TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Torrent Pharmaceuticals L
TORNTPHARM

Torrent Pharmaceuticals L Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 60/100 · Average See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹4,988.5

Change

+60.0 (1.22%)

Open

₹4,911.5

Prev. Close

₹4,928.5

Day High

₹4,990.5

Day Low

₹4,906.5

Volume Analysis

Traded

386,632

Delivered

252,493

Delivery %

65.31%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (27.4%)
  • •Strong operating margin (33.0%)

Weaknesses (2)

  • •High debt-to-equity ratio (1.79)
  • •Promoter holding is falling

Opportunities (2)

  • •Strong 3-year EPS growth (20.2%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹5,101.16 ₹5,045.83 ₹5,017.16 ₹4,961.83 ₹4,933.16 ₹4,877.83 ₹4,849.16
Fibonacci ₹5,045.83 ₹5,013.74 ₹4,993.92 ₹4,961.83 ₹4,929.74 ₹4,909.92 ₹4,877.83
Camarilla ₹5,011.6 ₹5,003.9 ₹4,996.2 ₹4,961.83 ₹4,980.8 ₹4,973.1 ₹4,965.4

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+29.63%

1 Week

+0.37%

1 Month

-1.22%

3 Months

+7.97%

6 Months

+21.34%

1 Year

+40.09%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹597.22

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

22.81%

Net margin 13.71% × asset turnover 0.32x × equity multiplier 5.2x

Company Overview

Sector

Healthcare

Market Cap

₹189,746 Cr

P/E (TTM)

85.0

ROE

27.4%

Book Value

₹248.0

Face Value

₹5.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Torrent Pharmaceuticals L lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 60/100. The strongest factor is Liquidity (95/100), while Valuation (3/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (27.4%); strong operating margin (33.0%); high debt-to-equity ratio (1.79); promoter holding is falling. Strong 3-year EPS growth (20.2%).

TopFund Score — Fundamentals Quality

60/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

12

Growth

70

Valuation

3

Cash Flow

74

Corporate Governance

69

Momentum

85

Institutional Ownership

74

Business Quality

70

Risk & Volatility

93

Liquidity

95

From Screener.in

  • +Company is expected to give good quarter
  • +Company has a good return on equity (ROE) track record: 3 Years ROE 26.2%
  • +Company has been maintaining a healthy dividend payout of 57.8%
  • −Stock is trading at 20.1 times its book value
  • −Promoter holding has decreased over last quarter: -7.53%
  • −The company has delivered a poor sales growth of 11.8% over past five years.
  • −Company might be capitalizing the interest cost

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 10 Sep 10 Sep
Announcement under Regulation 30 (LODR)-Newspaper Publication 09 Sep

Newspaper advertisement in respect of special window for transfer and dematerialisation of physical shares

Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot 07 Sep

Postal ballot passed appointing Shanti Ekambaram as Independent Director with 99.98% votes.

Shareholder Meeting / Postal Ballot-Scrutinizer"s Report 7 Sep 07 Sep
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 11 Aug

Intimation of Schedule of Investors Meet under Regulation 30 of SEBI (LODR) Regulations, 2015

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Sales + 2,591 2,660 2,732 2,745 2,859 2,889 2,809 2,959 3,178 3,302 3,303 4,197 4,921
Expenses + 1,800 1,835 1,863 1,862 1,955 1,950 1,895 1,995 2,146 2,219 2,215 2,841 3,257
Operating Profit 791 825 869 883 904 939 914 964 1,032 1,083 1,088 1,356 1,664
OPM % 31.0% 31.0% 32.0% 32.0% 32.0% 32.0% 33.0% 33.0% 32.0% 33.0% 33.0% 32.0% 34.0%
Other Income + 34 26 55 31 24 -16 33 -42 -37 -40 -23 -83 -33
Interest 103 91 80 80 75 64 57 56 56 48 45 236 305
Depreciation 191 201 213 203 197 198 199 201 201 204 206 508 593
Profit before tax 531 559 631 631 656 661 691 665 738 791 814 529 733
Tax % 29.0% 31.0% 30.0% 29.0% 30.0% 31.0% 27.0% 25.0% 26.0% 25.0% 22.0% 31.0% 23.0%
Net Profit + 378 386 443 449 457 453 503 498 548 591 635 364 566
EPS in Rs 11 11 13 13 14 13 15 15 16 17 19 11 17
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 4,636 6,687 5,816 5,950 7,673 7,939 8,005 8,508 9,620 10,728 11,516 13,980 15,723
Expenses + 3,616 3,954 4,438 4,601 5,690 5,769 5,524 6,077 6,778 7,360 7,795 9,421 10,532
Operating Profit 1,020 2,733 1,377 1,349 1,983 2,170 2,480 2,431 2,842 3,368 3,721 4,558 5,191
OPM % 22.0% 41.0% 24.0% 23.0% 26.0% 27.0% 31.0% 29.0% 30.0% 31.0% 32.0% 33.0% 33.0%
Other Income + 286 32 223 299 -300 121 57 -288 45 146 -1 -182 -179
Interest 175 184 206 308 504 451 353 255 333 354 252 385 634
Depreciation 191 238 307 409 618 654 658 662 707 808 795 1,119 1,511
Profit before tax 940 2,343 1,088 931 562 1,187 1,526 1,226 1,847 2,352 2,673 2,872 2,867
Tax % 20.0% 26.0% 14.0% 27.0% 22.0% 14.0% 18.0% 37.0% 33.0% 30.0% 28.0% 26.0% —
Net Profit + 751 1,733 934 678 436 1,025 1,252 777 1,245 1,656 1,911 2,138 2,156
EPS in Rs 22 51 28 20 13 30 37 23 37 49 56 64 64
Dividend Payout % 25.0% 34.0% 25.0% 35.0% 66.0% 53.0% 47.0% 105.0% 60.0% 57.0% 57.0% 59.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Reserves 2,406 3,409 4,266 4,538 4,640 4,739 5,753 5,868 6,029 6,687 7,421 8,219
Borrowings + 2,740 2,352 2,510 6,462 6,038 5,784 4,874 4,070 5,369 4,022 3,202 15,026
Other Liabilities + 2,589 3,040 2,740 3,159 3,351 3,402 3,363 2,884 3,043 3,627 3,603 20,200
Total Liabilities 7,820 8,886 9,601 14,243 14,113 14,010 14,075 12,906 14,610 14,505 14,396 43,614
Fixed Assets + 2,833 2,859 3,688 7,855 7,748 7,533 7,065 6,423 8,121 8,138 7,947 33,191
CWIP 678 1,042 519 647 617 712 889 630 765 361 478 641
Investments 298 780 804 492 353 2 181 226 199 173 156 948
Other Assets + 4,011 4,206 4,589 5,249 5,395 5,763 5,940 5,628 5,524 5,834 5,815 8,833
Total Assets 7,820 8,886 9,601 14,243 14,113 14,010 14,075 12,906 14,610 14,505 14,396 43,614
Equity Capital 85 85 85 85 85 85 85 85 169 169 169 169

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 810 2,742 1,009 894 1,798 1,393 2,005 1,803 2,368 3,266 2,585 3,023
Cash from Investing Activity + -2,113 -869 -798 -4,677 -246 229 -444 -196 -2,335 -160 -549 -12,630
Cash from Financing Activity + 1,212 -1,435 -193 3,417 -1,314 -1,549 -1,651 -1,781 77 -2,780 -2,298 10,151
Net Cash Flow -90 437 18 -366 238 73 -89 -174 110 327 -262 544
CFO/OP 85 121 101 87 105 77 88 91 97 112 86 84
Free Cash Flow 574 2,150 523 105 1,138 990 1,671 1,607 1,953 2,967 1,991 2,386

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 71.25% → 60.78%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Jul 2026
Public 7.46% 7.34% 7.25% 7.21% 7.17% 7.02% 6.93% 6.47% 6.41% 6.55% 6.42% 8.39%
Promoters 71.25% 71.25% 71.25% 71.25% 68.31% 68.31% 68.31% 68.31% 68.31% 68.31% 68.31% 60.78%
Government 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.1% 0.0% 0.1% 0.09%
FII 14.08% 14.14% 14.22% 14.46% 16.17% 16.31% 16.09% 15.92% 16.13% 16.18% 15.44% 17.97%
DII 7.11% 7.15% 7.17% 6.98% 8.25% 8.25% 8.54% 9.17% 9.05% 8.96% 9.73% 12.77%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Torrent Pharmaceuticals L (this stock) 189,746 85.0 20.11 27.4%
Apollo Hospitals Enter. L 128,055 60.9 13.51 21.2%
Divi S Laboratories Ltd 255,487 85.8 15.25 16.5%
Zydus Lifesciences Ltd 115,890 23.8 4.32 21.2%
Cipla Ltd 111,060 31.0 3.23 11.6%
Laurus Labs Limited 108,438 99.2 20.44 18.3%
Mankind Pharma Limited 102,225 47.9 6.27 13.1%

Which Mutual Funds Hold Torrent Pharmaceuticals L?

Frequently Asked Questions about Torrent Pharmaceuticals L

Community Sentiment

What are other investors saying about Torrent Pharmaceuticals L?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.